Prestige Consumer Healthcare (NYSE:PBH) announced its quarterly earnings results on Thursday. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.01, Morningstar.com reports. Prestige Consumer Healthcare had a positive return on equity of 12.45% and a negative net margin of 3.81%. The company had revenue of $232.15 million during the quarter, compared to analyst estimates of $231.52 million. During the same period in the prior year, the company earned $0.68 earnings per share. The firm’s revenue was down 8.6% on a year-over-year basis. Prestige Consumer Healthcare updated its FY 2020 guidance to $2.76-2.83 EPS and its FY20 guidance to $2.76-2.83 EPS.
Shares of NYSE PBH traded down $0.09 during midday trading on Friday, hitting $33.54. The company’s stock had a trading volume of 465,676 shares, compared to its average volume of 442,234. The company has a current ratio of 2.16, a quick ratio of 1.43 and a debt-to-equity ratio of 1.63. The business’s 50 day moving average price is $31.86. Prestige Consumer Healthcare has a 12-month low of $26.25 and a 12-month high of $41.76. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of 12.06, a P/E/G ratio of 1.91 and a beta of 0.91.
Several research firms have recently issued reports on PBH. CIBC reaffirmed a “hold” rating and issued a $84.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, May 27th. TheStreet raised Prestige Consumer Healthcare from a “d+” rating to a “c-” rating in a research note on Tuesday, July 23rd. ValuEngine raised Prestige Consumer Healthcare from a “strong sell” rating to a “sell” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research raised Prestige Consumer Healthcare from a “sell” rating to a “hold” rating and set a $31.00 price objective for the company in a research note on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $61.07.
Hedge funds and other institutional investors have recently modified their holdings of the company. Financial Gravity Wealth Inc. purchased a new stake in shares of Prestige Consumer Healthcare in the first quarter worth approximately $50,000. Quadrant Capital Group LLC increased its holdings in Prestige Consumer Healthcare by 2,979.3% during the 1st quarter. Quadrant Capital Group LLC now owns 1,786 shares of the company’s stock worth $53,000 after purchasing an additional 1,728 shares during the period. FDx Advisors Inc. purchased a new position in Prestige Consumer Healthcare during the 2nd quarter worth $245,000. Bailard Inc. purchased a new position in Prestige Consumer Healthcare during the 1st quarter worth $245,000. Finally, Diversified Trust Co increased its holdings in Prestige Consumer Healthcare by 8.2% during the 2nd quarter. Diversified Trust Co now owns 8,575 shares of the company’s stock worth $272,000 after purchasing an additional 650 shares during the period.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
See Also: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.